ALAMEDA, Calif., March 30 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN), maker of advanced imaging systems to accelerate drug discovery
and development, today announced that David W. Carter, chairman and chief
executive officer, and Pamela Reilly Contag, president, will present at the
CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
at the Millennium Broadway Hotel in New York.
The presentation will take place at 3:15 p.m. (Eastern) on Tuesday, April
5, 2005. There will be a live audio webcast of the presentation, which will
be accessible through a link posted on the investor relations section of
Xenogen's website at http://www.xenogen.com. The webcast will be available for
replay on Xenogen's website through April 19, 2005.
About Xenogen Corporation
Xenogen combines systems biology and low-light optical imaging to create
powerful new biophotonic imaging technology that advances the ability of
scientists to explore genes, proteins, pathogens and tumor cells in living
animals in real time, providing predictive data that is designed to
substantially improve the success rate in drug development. Xenogen
incorporates into living animals the bioluminescent gene that makes a firefly
glow and harnesses the resulting light using an ultra-sensitive camera and
sophisticated software. This biophotonic imaging technology creates images and
analyzes the resulting data on cellular activity, gene expression, and spread
of disease or the effect of a new drug candidate. Xenogen's biophotonic
imaging technology is used by leading academics and pharmaceutical and
biotechnology companies to provide more accurate and previously unavailable
data that is intended to result in the ability to make more timely and cost-
effective decisions at every step in the drug development process.
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
William A. Albright, Chief Financial Officer
of Xenogen Corporation, +1-510-291-6100
|
